RxDoctor Payments Data

Anthony Kramer

Psychiatric/Mental Health · Bemidji, MNNPI 1972997831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 28.4% of the total. Reporting peaked in 2021 at $138 and has fallen 85.4% since, to $20 in 2025.

$304in general payments, 2019–2025

Across 22 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$86
  • Sunovion Pharmaceuticals Inc.$53
  • Eisai Inc.$29
  • Takeda Pharmaceuticals U.S.A., Inc.$26
  • E.r. Squibb & Sons, L.L.C.$20
  • Lundbeck LLC$17
  • plus $72 from 5 others

What the payments were for

  • Food & beverage$304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$304 in reported general payments places this provider in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

See all psychiatric/mental health providers in Minnesota

Medicare billing

Part B allowed, 2024
$36,354
Medicare patients
99
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole89$119,526
Abilify MaintenaAripiprazole33$100,060
LatudaLurasidone Hcl24$34,237
Risperdal ConstaRisperidone Microspheres13$30,046
CaplytaLumateperone Tosylate17$24,740
Aripiprazole250$24,340
Clozapine199$20,494
VraylarCariprazine Hcl12$16,592
Lurasidone Hcl103$13,778
TrintellixVortioxetine Hydrobromide29$13,259
Asenapine Maleate24$12,697
Olanzapine305$10,001
Divalproex Sodium ErDivalproex Sodium100$8,632
Adderall XrDextroamphetamine/Amphetamine38$7,912
Olanzapine OdtOlanzapine37$7,265

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$15$219,585122 claims
Johnson & JohnsonRisperdal Consta, Concerta$11$35,33325 claims
Sunovion Pharmaceuticals Inc.Latuda$53$34,23724 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$26$19,78846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.

Other psychiatric/mental health in Bemidji

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →